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Background
In sub-Saharan Africa large numbers of clade C HIV-
infected individuals are exposed to antiretrovirals through
prevention of mother-to-child transmission and through
first-line non-nucleoside reverse transcriptase inhibitor-
based (NNRTI) regimens. HIV drug resistance pre-treat-
ment, as well as in those failing first-line ART, has not
been adequately catalogued. Choice of second-line ther-
apy would ideally be based on patterns of resistance at
first-line failure.
Methods
Genotypic resistance testing was performed on plasma
samples from both treatment-naïve individuals and those
failing first-line ART (confirmed HIV-RNA >1000 copies/
ml) from public sector clinics in the Greater Cape Town
area (2002–2007). We compared genotypic resistance
profiles for ART-naïve patients and those who have failed
ART. We examined whether time of genotyping was asso-
ciated with differential distribution of resistance muta-
tions.
Summary of results
Samples from 230 patients (120 naïve; 110 with virologic
failure) were included. 98% had clade C virus. Among
naïve patients, prevalence of primary resistance was esti-
mated at 2.5% (95% CI: 0.0%–5.3%). Three ART-naïve
patients each had one important RT mutation: K65R,
Y181C, G190A. Among NNRTI-treatment experienced
patients, the estimated prevalence of resistance mutations
was high. Ninety-six individuals (83%) had therapy-lim-
iting NNRTI mutations, including K103N (53%), V106M
(31%), Y181C (9.4%). Eighty-one individuals (70%) had
≤2 NNRTI mutations; 15 (13%) had >3 NNRTI muta-
tions. The M184V mutation was the most common single
mutation in 91 patients (78%). Eleven of the patients
with virologic breakthrough (9.5%) had the K65R muta-
tion. A non-significant trend toward more individuals
developing thymidine analogue mutations was noted
when genotype was completed after 6 months on failing
therapy [10/31 patients (32%)], compared to those who
had genotyping before 6 months [16/79 patients (20%)].
Conclusion
Prevalence of primary resistance in a sample of ART-naïve
clade C HIV-infected individuals in South Africa is low. An
NNRTI-based initial ART regimen remains appropriate for
most naive individuals. Patients failing first-line ART have
generally developed resistance to both NNRTIs and
NRTIs, the two drug classes used in first-line therapy. The
emergence of the K65R mutation, without tenofovir use,
is unexpected and worrisome. Current second-line ART
options remain viable, but close ongoing surveillance of
resistance patterns is critical to optimize clinical care.
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